



(51) International Patent Classification:

C07D 235/18 (2006.01) C07D 473/26 (2006.01)

C07D 471/04 (2006.01) A61K 31/52 (2006.01)

A61P 35/00 (2006.01)

(21) International Application Number:

PCT/IB2023/062262

(22) International Filing Date:

05 December 2023 (05.12.2023)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/386,263 06 December 2022 (06.12.2022) US

63/497,847 24 April 2023 (24.04.2023) US

(71) Applicant: ASTRAZENECA AB [SE/SE]; SE-151-85 Södertälje (SE).

(72) Inventors: **BARLAAM, Bernard**; AstraZeneca UK Limited, 1 Francis Crick Ave., Cambridge Biomedical Campus, Cambridge Cambridgeshire CB2 0AA (GB). **BODNARCHUK, Michael**; AstraZeneca UK Limited, 1 Francis Crick Ave., Cambridge Biomedical Campus, Cambridge Cambridgeshire CB2 0AA (GB). **WRIGLEY, Gail**; AstraZeneca UK Limited, 1 Francis Crick Ave., Cambridge Biomedical Campus, Cambridge Cambridgeshire CB2 0AA (GB). **WINTER-HOLT, Jon**; AstraZeneca UK Limited, 1 Francis Crick Ave., Cambridge Biomedical Campus, Cambridge Cambridgeshire CB2 0AA (GB). **TURNER, Oliver**; AstraZeneca UK Limited, 1 Francis Crick Ave., Cambridge Biomedical Campus, Cambridge Cambridgeshire CB2 0AA (GB). **GOPALSAMY, Ariamala**; AstraZeneca Pharmaceuticals LP, 1800 Concord Pike, P.O. Box 15437, Wilmington, Delaware 19850-5437 (US). **SHIELDS, Jason**; AstraZeneca Pharmaceuticals LP, 1800 Concord Pike, P.O. Box 15437, Wilmington, Delaware 19850-5437 (US). **FERRER-CABRERA, Sofia**; AstraZeneca UK Limited, 1 Francis Crick Ave., Cambridge Biomedical Campus, Cambridge Cambridgeshire CB2 0AA (GB).

(74) Agent: **ASTRAZENECA INTELLECTUAL PROPERTY**; Eastbrook House, Shaftesbury Road, Cambridge Cambridgeshire CB2 8BF 6GH (GB).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, CV, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).


Declarations under Rule 4.17:

— as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))

Published:

— with international search report (Art. 21(3))
— in black and white; the international application as filed contained color or greyscale and is available for download from PATENTSCOPE

(54) Title: POLQ INHIBITORS



(I)

(57) Abstract: The specification generally relates to compounds of Formula (I): (I), or a stereoisomer or pharmaceutically salt thereof, wherein G, G_a, G_b, X, Y, R¹, R², Q¹, Q², and Q³ have any of the meanings defined herein, together with compositions containing them and their use in therapy. The compounds are inhibitors of the polymerase, DNA polymerase theta (Polθ or POLQ), and are thereby particularly useful in the treatment of cancer.



WO 2024/121753 A1